This clinical trial is focused on studying resistant hypertension, a condition where blood pressure remains high despite using at least three different types of blood pressure medications, including a diuretic. The study will test a new treatment called Baxdrostat, which is a synthetic small molecule taken as a tablet. Participants in the study will either receive Baxdrostat or a placebo, which looks like the medication but does not contain the active substance.
The purpose of the study is to determine if Baxdrostat can effectively reduce blood pressure in people with resistant hypertension. Participants will be randomly assigned to receive either Baxdrostat or the placebo. The study will last for several weeks, during which participants will take the assigned tablets and have their blood pressure monitored regularly. The main focus will be on changes in blood pressure over a 24-hour period at the end of the study.
Throughout the study, participants will continue their usual blood pressure medications alongside the trial treatment. The goal is to see if Baxdrostat can help lower blood pressure more effectively than the placebo. This research aims to provide new insights into managing resistant hypertension and improving treatment options for those affected by this condition.
Belgium 
Bulgaria 
Czechia 
Germany 
Greece 
Hungary 
Poland 
Slovakia 
Spain 
